The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.
Akira Ueda
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Yoshimitsu Kobayashi
No relevant relationships to disclose
Ayumu Hosokawa
No relevant relationships to disclose
Ayako Doi
No relevant relationships to disclose
Yasushi Tsuji
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Yutaka Watanabe
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Kazunori Eto
No relevant relationships to disclose
Tomoyuki Ohta
No relevant relationships to disclose
Takenori Takahata
No relevant relationships to disclose
Shinichiro Ikeda
No relevant relationships to disclose
Hiroshi Nakatsumi
No relevant relationships to disclose
Kazuhiro Iwai
No relevant relationships to disclose
Kanji Kato
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult